Trials / Recruiting
RecruitingNCT07354711
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
A Phase I/II Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- Sponsor
- 3H Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 3H-10000 | 3H-10000 will be administered by infusion Q2W in 28-day cycles. |
Timeline
- Start date
- 2026-01-04
- Primary completion
- 2028-01-01
- Completion
- 2029-01-01
- First posted
- 2026-01-21
- Last updated
- 2026-01-21
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07354711. Inclusion in this directory is not an endorsement.